These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29799521)

  • 1. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
    Yallowitz A; Ghaleb A; Garcia L; Alexandrova EM; Marchenko N
    Cell Death Dis; 2018 May; 9(6):621. PubMed ID: 29799521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
    Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
    Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
    Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
    Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
    Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
    Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
    BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
    Li D; Marchenko ND
    Oncotarget; 2017 Jan; 8(4):5823-5833. PubMed ID: 27791982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition.
    Pastorek M; Muller P; Coates PJ; Vojtesek B
    PLoS One; 2018; 13(8):e0202758. PubMed ID: 30138434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
    Zhang J; Li Q; Wu Y; Wang D; Xu L; Zhang Y; Wang S; Wang T; Liu F; Zaky MY; Hou S; Liu S; Zou K; Lei H; Zou L; Zhang Y; Liu H
    Cell Commun Signal; 2019 Feb; 17(1):15. PubMed ID: 30786890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV; Reginato MJ
    Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
    Jegg AM; Ward TM; Iorns E; Hoe N; Zhou J; Liu X; Singh S; Landgraf R; Pegram MD
    Breast Cancer Res Treat; 2012 Dec; 136(3):683-92. PubMed ID: 23089982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
    Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.
    Li D; Yallowitz A; Ozog L; Marchenko N
    Cell Death Dis; 2014 Apr; 5(4):e1194. PubMed ID: 24763051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.
    Yang ZY; Yang L; Xu CW; Wang XJ; Lei L
    Biol Open; 2020 Jan; 9(1):. PubMed ID: 31980423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
    Xia W; Bacus S; Husain I; Liu L; Zhao S; Liu Z; Moseley MA; Thompson JW; Chen FL; Koch KM; Spector NL
    Mol Cancer Ther; 2010 Feb; 9(2):292-9. PubMed ID: 20124457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
    Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
    Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
    Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
    Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.
    Stuhlmiller TJ; Miller SM; Zawistowski JS; Nakamura K; Beltran AS; Duncan JS; Angus SP; Collins KA; Granger DA; Reuther RA; Graves LM; Gomez SM; Kuan PF; Parker JS; Chen X; Sciaky N; Carey LA; Earp HS; Jin J; Johnson GL
    Cell Rep; 2015 Apr; 11(3):390-404. PubMed ID: 25865888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation.
    Huynh TK; Ho CY; Tsai CH; Wang CK; Chen YJ; Bau DT; Tu CY; Li TS; Huang WC
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.